Peptide
MOTS-c
MOTS-c (Mitochondrial Open Reading frame of the Twelve S rRNA type-c)
A 16-amino-acid peptide encoded inside the mitochondrial genome. Falling with age, restoring exercise capacity in aged mice, and now in early human observational work as an insulin-sensitizing agent.
Summary Does MOTS-c really improve aging, exercise, or blood sugar? Show / hide ↓
MOTS-c is a natural 16-amino-acid peptide, a small protein-like substance made from mitochondrial DNA, the genetic material in cells’ energy centers. Its levels appear to fall with age, and small human observational studies link lower levels with insulin resistance, meaning the body has trouble controlling blood sugar, and higher body fat. In older mice, MOTS-c improved blood-sugar control and restored running ability, but animal results do not prove the same benefits in people. A phase 1 safety study of a MOTS-c-like drug in people with fatty liver disease found tolerable safety and early metabolic signals, but no completed trial has randomly assigned enough people to test meaningful health outcomes. Some users take 5 mg three to five times weekly, but long-term safety is unknown.
What this means for you: MOTS-c is promising mainly because of animal research, not proven human benefits. There is not enough evidence to buy or use it for longevity or exercise.
early evidenceMOTS-c is one of the more compelling entries in the modern peptide literature because it is not a synthetic construct. It is an endogenous peptide encoded in the mitochondrial genome that circulates in human blood, falls with age, and correlates inversely with insulin resistance and body fat in cross-sectional human data.
The mechanism, mapped by Cohen and colleagues in a series of papers since 2015, runs through AMPK activation. MOTS-c enters cells, translocates to the nucleus under metabolic stress, and modulates nuclear gene expression governing glucose disposal and lipid metabolism. In aged mice, exogenous MOTS-c administration restored insulin sensitivity, reduced diet-induced obesity, and, in a 2018 paper in Cell Metabolism, restored running-wheel performance in old animals to near-young levels.
Human data is starting to arrive. Cross-sectional studies of Japanese and Korean cohorts have found lower circulating MOTS-c in obese and diabetic subjects, with restoration after exercise interventions. A phase 1 safety trial of a MOTS-c analog (CB4211) for NAFLD was completed by CohBar Inc., which had licensed the peptide, with tolerable safety and preliminary metabolic signals. CohBar shut down operations in 2023 before advancing to phase 2, and the licensing has not been picked up by another pharmaceutical company as of 2026.
Inside the biohacking community, MOTS-c is used at 5 mg subcutaneous three to five times per week, on the theory that pulsatile dosing mimics the physiologic pattern. Users report improved training capacity and energy at these doses, consistent with the animal exercise data. Long-term safety data does not exist.
Our position: MOTS-c sits at Tier 4. The endogenous origin, the AMPK mechanism, and the mouse exercise data are unusually good for a peptide in this space. What is missing is a randomized controlled trial in humans that lasts long enough to see meaningful metabolic endpoints. That trial has not been run since CohBar collapsed, and no successor sponsor has emerged.
MOTS-c, a mitochondrial-derived peptide studied for insulin sensitivity, has its first randomized human trial recruiting in 2026 after a decade of mouse-only data, and received the weakest PCAC vote support of the six approved-for-review peptides.
Verified 2026-08-06. We update this section as PCAC decisions, ClinicalTrials.gov entries, and new peer-reviewed studies land.
FDA / PCAC (July 2026)
Reviewed July 23-24, 2026. The PCAC voted 7-5-2 to recommend MOTS-c for the 503A Bulks List, the weakest margin among the six peptides that received favorable votes, against FDA staff's own briefing document recommending against inclusion (https://www.fda.gov/media/193343/download). The vote is advisory and non-binding (https://validusbio.com/learn/pcac-2026-peptide-vote-results/).
US status
Not FDA approved for any indication; not currently on the 503A Bulks List. Removed from FDA's Category 2 list in April 2026 after its nomination was withdrawn.
EU status
Not authorised for human use in EU as of 2026.
Best-supported claim
MOTS-c is a genuine, endogenously produced 16-amino-acid mitochondrial-derived peptide, not a synthetic novelty, and a 2023 review in Frontiers in Endocrinology summarizes consistent animal and cell data linking it to glucose metabolism regulation, insulin sensitivity, and cellular stress response (https://pmc.ncbi.nlm.nih.gov/articles/PMC9905433/). A phase 2a randomized controlled trial in prediabetic, overweight adults is now recruiting (NCT07505745), which will be the first placebo-controlled human efficacy data for this peptide (https://clinicaltrials.gov/study/NCT07505745).
Not supported by the evidence base
Longevity vendor content describes MOTS-c as a proven "exercise mimetic" and anti-aging agent based entirely on mouse studies showing it prevents diet-induced obesity and age-dependent insulin resistance in rodents (https://peptiq.io/blog/mots-c-prediabetes-trial-2026). No human trial has reported any metabolic, longevity, or exercise-performance outcome as of August 2026. The phrase "entering human trials" gets recycled by multiple retail blogs as though enrollment were equivalent to proven efficacy; the trial has not completed, let alone reported results.
Typical usage
5-10 mg subcutaneous injection, 2-3 times weekly, in research and compounding protocols; the registered phase 2a trial uses a 12-week treatment period, but doses used in that trial have not been publicly disclosed as of August 2026.
Safety
No completed human trial has reported safety data. FDA's July 2026 briefing document lists MOTS-c among substances with unassessed immunogenicity risk for injectable peptide formulations (https://www.fda.gov/media/193343/download). The ongoing phase 2a trial includes a 4-week post-treatment safety follow-up specifically because prior human safety data are sparse (https://clinicaltrials.gov/study/NCT07505745). People with type 1 diabetes or on insulin therapy should avoid self-administration outside a monitored trial given its direct glucose-regulating mechanism and unknown hypoglycemia risk in combination with other glucose-lowering drugs.
Interactions worth flagging
- No formal drug-interaction studies exist
- Theoretical additive hypoglycemia risk with insulin or sulfonylureas given glucose-regulating mechanism
- Unknown interaction with metformin or GLP-1 receptor agonists
Three recent studies to know
-
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
First randomized, double-blind, placebo-controlled phase 2a trial of MOTS-c is recruiting to test efficacy and safety in prediabetic overweight adults.
Read study → -
MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation
Review of mouse and cell data links MOTS-c to glucose regulation, insulin sensitivity, and mitochondrial-nuclear signaling; no human RCT data are summarized.
Read study → -
What the FDA's July 2026 PCAC Peptide Review Decided
PCAC voted 7-5-2 to recommend MOTS-c for the 503A Bulks List, the narrowest margin of the six peptides approved for review; non-binding.
Read study →
Further reading
Curated external sources for a deeper dive. External links open in a new tab.